Aquilus Pharmaceuticals is a neurotherapeutics company advancing AQU-118, a novel, orally available matrix metalloproteinase (MMP) inhibitor, for the treatment of ALS. The company has secured significant non-dilutive grant funding from the ALS Association, NIH, and the Department of Defense, and has cleared its IND for a Phase 1 trial slated for early 2026. With a lean, experienced leadership team and prestigious academic collaborators, Aquilus is positioned to address a critical unmet need in a devastating disease with no approved MMP inhibitors on the market.
Small molecule, semi-selective inhibitors of Matrix Metalloproteinases (MMPs), specifically MMP-9 and MMP-2, for neurodegenerative diseases.
Funding History
7
Total raised:$3.6M
Grant$458KNINDS
Grant$1.4MNIDCR
Grant$287KNCI
Grant$556KNIDCR
Opportunities
The primary opportunity is addressing the critical unmet need in ALS with a first-in-class MMP inhibitor, which could command a premium price and achieve rapid adoption in a supportive regulatory environment.
Success in ALS could validate the MMP platform for expansion into other neurodegenerative diseases, such as certain dementias or multiple sclerosis, significantly broadening the market.
Risk Factors
The key risks are the high clinical failure rate in ALS and the unproven nature of MMP inhibition for this indication.
The company also faces significant financial risk as a pre-revenue, single-asset private company reliant on raising a Series A round to fund costly clinical trials.
Competitive and safety risks for the novel mechanism also persist.
Competitive Landscape
The ALS competitive landscape includes approved symptomatic/slowing therapies (riluzole, edaravone, AMX0035) and numerous companies investigating diverse mechanisms (anti-sense oligonucleotides, gene therapy, neuroinflammation). Aquilus's primary competitive differentiation is its first-in-class oral MMP-9/MMP-2 inhibitor approach, for which there are no direct competitors in late-stage development for ALS.
